IGF-1 LR3 Safety and Side Effects in Research
For research purposes only. Not for human use.
Long R3 IGF-1 (IGF-1 LR3) is an engineered insulin-like growth factor analog used primarily as a laboratory reagent. It is not FDA-approved for human use. Direct human safety trials of LR3 are not available in the indexed evidence reviewed here, so a scientifically responsible safety profile must distinguish LR3-specific laboratory and animal findings from clinical evidence about native recombinant human IGF-1 (mecasermin).
The central evidence limitation
Most confident-sounding online safety claims about IGF-1 LR3 are not supported by controlled human LR3 studies. A forensic case report identified His-tagged Long R3 IGF-I in a black-market vial and explicitly stated that the effects of the tagged product in humans had not been elucidated or described (PMID: 20675162; DOI: 10.1016/j.ghir.2010.07.001). That finding establishes an identity and quality-control problem, not a human dosing or safety profile.
| Evidence layer | What it can show | What it cannot show |
|---|---|---|
| Cell and isolated-tissue experiments | Receptor signaling and direct tissue responses | Human adverse-event rates or safe exposure |
| Animal studies | Systemic biological activity and target-organ hypotheses | Human dosing, incidence, or long-term safety |
| Native IGF-1 medicine label | Class-related hazards worth considering | That LR3 has identical pharmacokinetics or risk |
| Black-market case analysis | Mislabeling/tagging and manufacturing uncertainty | Clinical tolerability |
What LR3-specific experiments show
LR3 activates IGF-1 receptor pathways
Cell experiments show that Long R3 IGF-I can induce IGF-1 receptor phosphorylation. IGF-binding protein 3 inhibited LR3-induced receptor phosphorylation in vitro, supporting receptor-mediated biological activity while also demonstrating that binding-protein interactions are more nuanced than the common claim that LR3 is completely “binding-protein resistant” (PMID: 11735239; DOI: 10.1054/ghir.2001.0231).
Receptor activation is a mechanism, not proof of a particular human adverse effect. It does, however, justify evaluating metabolic and proliferative endpoints rather than treating LR3 as biologically inert.
Animal studies demonstrate systemic and growth-related effects
In rats, seven days of LR3 exposure increased intestinal glucose-analog absorption when expressed per centimeter of jejunum, an effect the authors attributed mainly to increased mucosal mass (PMID: 11999215; DOI: 10.1080/08977190290022194). In lactating mice, LR3 increased mammary Akt phosphorylation and altered gene expression, with a modest increase in lactation capacity (PMID: 18577570; DOI: 10.1677/JOE-07-0556). These are animal findings; neither study measured adverse events in people.
An isolated bovine and ovine artery study found LR3 altered noradrenaline responses, with evidence for nitric-oxide-dependent effects in bovine vessels (PMID: 10825414). Because the work used isolated ruminant tissue, it cannot establish cardiovascular safety or risk in humans.
Why hypoglycemia is a plausible concern—but not a quantified LR3 human rate
The FDA-approved medicine mecasermin is recombinant human IGF-1 with the native human sequence, not LR3. Its FDA label carries a warning for severe hypoglycemia, including seizures, and lists hypoglycemia among common adverse reactions. This provides an authoritative class-related signal because IGF-1 can produce insulin-like metabolic effects.
It would be incorrect to transfer mecasermin incidence figures, instructions, or pharmacokinetics directly to LR3. LR3 is structurally modified, lacks an approved label, and has not been characterized in controlled human safety trials. The correct conclusion is that clinically important glucose lowering is biologically plausible and demands explicit laboratory risk assessment—not that a particular percentage or threshold is proven for LR3.
Proliferation and malignancy: hazard versus demonstrated outcome
IGF-1 receptor signaling regulates cell survival and proliferation. LR3-specific cell studies confirm pathway activation, and animal work demonstrates tissue-growth responses. The mecasermin label contraindicates use in active or suspected malignancy, providing additional class context. None of this proves that LR3 causes cancer in humans, because direct longitudinal human evidence is absent. It does mean researchers should not present sustained IGF-1R stimulation as risk-free or make unsupported claims about organ growth, facial changes, or irreversible acromegaly.
Other class-related concerns
The mecasermin label reports intracranial hypertension, lymphoid tissue hypertrophy, headache, and injection-site hypertrophy among recognized risks or adverse reactions. These observations concern native recombinant IGF-1 used under an approved indication. They are useful for selecting cautious research endpoints, but they are not LR3 adverse-event frequencies.
Product identity and contamination risk
The black-market analysis found a His-tag attached to the claimed LR3 product (PMID: 20675162). A research reagent may differ from its label in sequence, tag, purity, counterion, aggregation, sterility, or endotoxin burden. Those variables can create hazards unrelated to the intended molecule. A mass value on a certificate is not enough; researchers should assess identity, purity method, and lot traceability. See how to read a peptide certificate of analysis and our research-grade versus pharmaceutical-grade comparison.
Regulatory status
IGF-1 LR3 is not an FDA-approved drug. Mecasermin is FDA-approved for narrowly defined severe primary IGF-1 deficiency indications, but that approval does not extend to LR3. Structural similarity does not confer approval, interchangeability, an established dose, or a human safety profile.
Responsible research interpretation
- Label every claim as cell, isolated tissue, animal, native-IGF-1 clinical, or LR3-specific evidence.
- Do not translate animal exposure or mecasermin labeling into LR3 personal-use instructions.
- Prespecify glucose, receptor-signaling, proliferation, and product-quality endpoints where relevant.
- Document analytical identity, tags, endotoxin, aggregation, and lot provenance.
- Treat the absence of human LR3 trials as uncertainty, not evidence of safety.
Frequently asked questions
Is IGF-1 LR3 FDA-approved?
No. IGF-1 LR3 is not an FDA-approved medicine and has no approved human-use label.
Is IGF-1 LR3 the same as mecasermin?
No. Mecasermin is recombinant human IGF-1 with the native human sequence. LR3 is a modified analog; safety data and labeling cannot be treated as interchangeable.
Has IGF-1 LR3 been tested for safety in humans?
No controlled human LR3 safety trials were identified in the indexed evidence reviewed for this guide. Published LR3 work is predominantly laboratory or animal research.
Can IGF-1 LR3 cause hypoglycemia?
Glucose lowering is a biologically plausible class concern, and severe hypoglycemia is an established warning for native IGF-1 medicine. A human LR3 incidence rate or safe threshold has not been established.
Does IGF-1 LR3 cause cancer or acromegaly?
LR3 activates growth-related signaling, creating a legitimate proliferative hazard hypothesis. Direct human evidence proving that LR3 causes cancer or acromegaly is absent, so categorical claims in either direction are unsupported.
Is there a safe research dose for people?
No approved human dose exists, and this article does not provide clinical or personal-use instructions.
References
- Thevis M, et al. Growth Horm IGF Res. 2010. PMID: 20675162. DOI: 10.1016/j.ghir.2010.07.001.
- Ricort JM, et al. Growth Horm IGF Res. 2001. PMID: 11735239. DOI: 10.1054/ghir.2001.0231.
- Lo HC, et al. Growth Factors. 2002. PMID: 11999215. DOI: 10.1080/08977190290022194.
- Prosser CG, et al. J Endocrinol. 2008. PMID: 18577570. DOI: 10.1677/JOE-07-0556.
- Prosser CG, et al. J Endocrinol. 2000. PMID: 10825414.
- FDA. INCRELEX (mecasermin) prescribing information, 2019. Application 021839.
For research purposes only. Not for human use.